< Back LIVX 2026 8th – 10th December, 2026 Dubai, UAE Hosting the most powerful global ecosystem for longevity, biotech, and investment. ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

< Back LIVX 2026 8th – 10th December, 2026 Dubai, UAE Hosting the most powerful global ecosystem for longevity, biotech, and investment. ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

We assess the intricate manufacturing landscapes of cell and gene therapies, highlighting the distinct capabilities, regulatory environments, and market dynamics of North America, Europe, the Middle East, Africa, and the Asia-Pacific region. < Back CGT Manufacturing: A Comparative Analysis of APAC, EMEA, and NA Markets We assess the intricate manufacturing landscapes of cell and gene therapies, highlighting the distinct capabilities, regulatory environments, and market dynamics of North America, Europe, the Middle East, Africa, and the Asia-Pacific region. Cell and gene therapy (CGT) represents one of the most advanced and rapidly evolving fields in medicine, promising cures for diseases that were previously considered untreatable. However, the manufacturing process behind these therapies is highly complex, involving advanced biotechnological tools, stringent regulatory oversight, and significant logistical coordination. As the demand for CGT grows globally, manufacturing capabilities in different regions have become an essential focus. Here we explore the cell and gene therapy manufacturing landscape across three key markets: Asia-Pacific (APAC), Europe, the Middle East, and Africa (EMEA), and North America (NA), outlining the regional differences in capabilities, regulatory landscapes, and market dynamics. The Manufacturing Landscape in North America (NA) North America, specifically the United States, is the global leader in cell and gene therapy development and manufacturing. Home to some of the largest biopharmaceutical companies (such as Bluebird Bio and Thermo Fisher Scientific) and academic institutions pioneering CGT research (such as UCLA’s Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell and Stanford University’s Center for Definitive and Curative Medicine), North America’s dominance stems from its strong innovation ecosystem and robust funding mechanisms. Manufacturing Infrastructure : North America benefits from a mature biopharmaceutical manufacturing industry, with state-of-the-art facilities capable of producing both autologous and allogeneic therapies. Companies such as Bluebird Bio and Kite Pharma (a Gilead company) are pioneers in producing CAR-T cell therapies, gene-modified cell therapies, and gene therapies. The region has also seen a surge in contract development and manufacturing organizations (CDMOs), supporting scaling up production to meet rising demand. Regulatory Environment : The U.S. Food and Drug Administration (FDA) has established clear regulatory pathways for CGT products, such as the Breakthrough Therapy designation and the Regenerative Medicine Advanced Therapy (RMAT) designation. These pathways expedite the development and review of CGT products, fostering innovation while maintaining safety and efficacy standards. Challenges : Despite North America’s lead, the region still faces challenges in scaling up manufacturing due to the complexity of CGT production. Ensuring consistent product quality, controlling costs, and managing the supply chain, particularly for autologous therapies, remain significant hurdles. Furthermore, skilled labor shortages and high operating costs create bottlenecks in manufacturing capacity expansion. The Manufacturing Landscape in Europe, the Middle East, and Africa (EMEA) The EMEA region, specifically Europe, has also established itself as a major hub for cell and gene therapy innovation, with countries such as the United Kingdom, Germany, and Belgium leading in manufacturing capabilities. However, the market dynamics and regulatory environment in the EMEA region differ significantly from those in North America. Manufacturing Infrastructure : While Europe houses world-class manufacturing facilities, the region has historically lagged behind North America in terms of production capacity. Nonetheless, recent years have seen significant investment in expanding CGT manufacturing in Europe. For example, companies such as Lonza and Oxford Biomedica have established advanced facilities focused on viral vector production and cell therapy manufacturing. The European market is also seeing increasing participation from CDMOs, which are key in scaling production for smaller biotech firms. Regulatory Environment : The European Medicines Agency (EMA) has its own distinct regulatory pathways for cell and gene therapies, such as the PRIME (PRIority MEdicines) scheme. The EMA’s regulatory framework is harmonized across the European Union, simplifying market access for CGT manufacturers. However, the complex national-level pricing and reimbursement systems across different EU member states can pose challenges for companies in navigating market access and achieving commercial success. Challenges : One of the primary challenges in the EMEA region is the fragmented nature of the market. While there is regulatory harmonization, there are still discrepancies in national healthcare systems, pricing, and reimbursement policies. Moreover, Europe faces a similar issue as North America in terms of scaling up manufacturing, particularly with respect to maintaining cost efficiencies in a highly regulated environment. The Manufacturing Landscape in Asia-Pacific (APAC) The APAC region, particularly China, Japan, and South Korea, is emerging as a key player in the global CGT market. The region’s growing biotech sector, increasing government support, and large patient population make it a strategic market for cell and gene therapy development and manufacturing. Manufacturing Infrastructure : While APAC's CGT manufacturing infrastructure is still developing, it is rapidly expanding. Countries such as China and Japan have made significant strides in building advanced manufacturing capabilities. China, in particular, has seen a boom in the construction of CGT manufacturing facilities, with both domestic companies like WuXi AppTec and foreign companies expanding their presence in the region. Japan, with its focus on regenerative medicine, has also developed specialized manufacturing hubs, supported by initiatives such as the Japanese Regenerative Medicine Promotion Act. Regulatory Environment : One of the distinctive features of the APAC market is its relatively fast regulatory approvals for CGT products. China’s National Medical Products Administration (NMPA) and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) have implemented expedited regulatory pathways for regenerative medicine products. In Japan, for example, the “conditional time-limited approval” system allows early market access for promising therapies with provisional approval based on limited clinical data. Challenges : Despite its rapid growth, the APAC region faces several challenges in CGT manufacturing. A lack of standardized regulations across the region creates difficulties for multinational companies seeking to enter multiple APAC markets. Additionally, the high cost of manufacturing and ensuring supply chain integrity remain significant issues. While China and Japan have made considerable strides, other APAC countries still face infrastructure gaps in terms of manufacturing capacity and expertise. Key Differences and Comparative Insights Regulatory Frameworks : The regulatory landscape is one of the most distinct differences between these regions. While North America has a well-defined and streamlined regulatory process, EMEA’s market is more fragmented (despite efforts aimed at harmonization). In contrast, APAC has shown remarkable flexibility in expediting approvals, though regulatory standards vary widely across countries, making cross-border commercial strategies complex. Manufacturing Capacity and Expertise : North America leads in terms of established manufacturing infrastructure and expertise. However, Europe is quickly catching up, particularly with the increase in CDMO activities. APAC, while growing rapidly, still faces a gap in manufacturing infrastructure, especially outside of major markets like China and Japan. Market Dynamics : North America remains the largest market for CGT products, driven by a strong investment landscape and extensive healthcare reimbursement systems. Europe, while advanced in scientific innovation, struggles with market access due to complex pricing and reimbursement processes. The APAC region, with its large patient population and increasing government support, offers significant growth potential but remains fragmented in terms of market access and regulatory consistency. Market leaders Based on 2023 end of year figures, the top cell and gene therapy companies as judged by single therapy revenue is as follows: 1. Kite, a Gilead Company (USA) Yescarta (axicabtagene ciloleucel) is a CAR-T cell therapy developed by Kite Pharma, a subsidiary of Gilead Sciences. It was one of the first CAR-T therapies to gain approval and represents a significant advancement in cancer treatment, specifically for certain types of blood cancers. 2023 revenue: $1.5 billion 2. Novartis (Switzerland) Zolgensma (onasemnogene abeparvovec) is a groundbreaking gene therapy developed by Novartis for the treatment of spinal muscular atrophy (SMA), a rare genetic disorder that affects motor neurons, leading to muscle weakness and loss of movement. It is the first and only gene therapy approved to treat this condition. 2023 revenue: $1.2 billion 3. Novartis (Switzerland) Kymriah (tisagenlecleucel) is a pioneering CAR-T cell therapy developed by Novartis for the treatment of certain blood cancers. It was the first CAR-T therapy to receive FDA approval and has since been a landmark in the field of personalized cancer treatments. 2023 revenue: $508 million 4. Janssen Biotech, Johnson & Johnson (USA), and Legend Biotech (USA) Carvykti (ciltacabtagene autoleucel) is a CAR-T cell therapy co-developed by Legend Biotech and Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson) for the treatment of relapsed or refractory multiple myeloma. It is an innovative therapy that offers a personalized treatment approach for patients with advanced stages of this blood cancer. 2023 revenue: $500 million 5. Bristol Myers Squibb (USA) and 2seventy bio (USA) Abecma (idecabtagene vicleucel) is a CAR-T cell therapy developed by Bristol Myers Squibb and 2seventy bio for the treatment of relapsed or refractory multiple myeloma. It is the first FDA-approved CAR-T therapy specifically targeting this form of cancer, providing a new treatment option for patients who have exhausted other therapies. 2023 revenue: $472 million Conclusion Cell and gene therapy manufacturing is a complex and evolving field, with significant regional differences in terms of infrastructure, regulatory oversight, and market dynamics. While North America currently dominates CGT manufacturing, EMEA and APAC are quickly advancing, each with unique strengths and challenges. As the global CGT market continues to expand, manufacturers will need to navigate these regional distinctions to optimize production and market access strategies, ensuring that life-saving therapies reach patients worldwide. Author BioFocus Newsroom Previous Next

< Back 12th – 15th January, 2026 San Francisco, CA J.P. Morgan Healthcare Conference The 44th Annual Healthcare Conference will take place on January 12-15, 2026 in San Francisco, California. This premier conference is the largest and most informative healthcare investment symposium in the industry, which connects global industry leaders, emerging fast-growth companies, innovative technology creators and members of the investment community. Previous Register now Next

< Back LIVX 2026 8th – 10th December, 2026 Dubai, UAE Hosting the most powerful global ecosystem for longevity, biotech, and investment. ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

< Back LIVX 2026 8th – 10th December, 2026 Dubai, UAE Hosting the most powerful global ecosystem for longevity, biotech, and investment. ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

< Back LIVX 2026 8th – 10th December, 2026 Dubai, UAE Hosting the most powerful global ecosystem for longevity, biotech, and investment. ! Widget Didn’t Load Check your internet and refresh this page. If that doesn’t work, contact us. Previous Next

Novartis' Phase III study of intrathecal onasemnogene abeparvovec for spinal muscular atrophy (SMA) successfully met its primary endpoint, showing significant motor function improvements. < Back Novartis' Intrathecal Onasemnogene Abeparvovec Phase III Study Meets Primary Endpoint Novartis' Phase III study of intrathecal onasemnogene abeparvovec for spinal muscular atrophy (SMA) successfully met its primary endpoint, showing significant motor function improvements. Novartis announced today that its Phase III study of intrathecal onasemnogene abeparvovec (brand name: Zolgensma) has successfully met its primary endpoint, showing significant clinical improvements in children and young adults with spinal muscular atrophy (SMA). The data from this global trial marks a promising step forward in the treatment of SMA, a rare, genetic neurodegenerative disease that leads to muscle weakness and, in severe cases, early death. The trial evaluated the efficacy and safety of onasemnogene abeparvovec delivered via intrathecal (directly into the spinal fluid) injection, a delivery method designed to target the central nervous system more effectively. The primary endpoint of the study was the improvement in motor function, as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE), a widely used assessment for SMA. The results showed statistically significant improvements in motor function for children and young adults treated with the therapy compared to baseline measures. SMA, caused by mutations in the SMN1 gene, leads to a progressive loss of motor neurons, significantly impairing muscle strength and movement. Prior to the approval of Zolgensma in its current form (IV administration), treatment options were limited, and the disease often led to irreversible damage and early death, particularly in the most severe cases, such as SMA Type 1. This intrathecal formulation of onasemnogene abeparvovec is designed to address the needs of older patients who may not have been eligible for intravenous treatment. By offering a new, potentially more effective delivery method for the therapy, Novartis aims to broaden the impact of Zolgensma, especially in those with later-onset forms of SMA who still experience significant functional decline. "This milestone represents a significant advancement in SMA care and brings hope to patients who have been previously underserved by available treatments," said Nimisha Nair, Global Head of Neurosciences at Novartis. "We are excited by the potential of intrathecal Zolgensma to offer a meaningful treatment option for a broader range of children and young adults with SMA." The study also assessed the safety profile of the intrathecal formulation. According to Novartis, the treatment was generally well-tolerated, with no new safety concerns identified compared to the previously approved intravenous formulation. The company is now preparing to submit these findings to regulatory authorities worldwide, with the hope of expanding the approved indications for onasemnogene abeparvovec to include intrathecal administration. If approved, this new method of delivery could provide a significant therapeutic option for SMA patients, potentially improving quality of life and delaying disease progression. About Onasemnogene Abeparvovec (Zolgensma) Zolgensma is a gene therapy that works by replacing the missing or nonfunctional SMN1 gene with a fully functional copy, aiming to address the underlying cause of SMA. It was initially approved by the U.S. FDA in 2019 for use in children under 2 years of age and has since been shown to improve motor function in infants with SMA. The new intrathecal formulation expands its potential use to a broader age range. The results from this Phase III study come as a beacon of hope for the SMA community, where early intervention remains crucial. With SMA affecting approximately 1 in 10,000 live births globally, the treatment landscape has evolved rapidly, and Novartis is positioning Zolgensma as a cornerstone of therapy for the disease. Author BioFocus Newsroom Previous Next

A new international collaboration is building more representative stem cell models of ALS, an effort that could improve drug discovery and reduce clinical trial failure rates. < Back PRISM ALS Sets Out to Improve ALS/MND Drug Discovery A new international collaboration is building more representative stem cell models of ALS, an effort that could improve drug discovery and reduce clinical trial failure rates. A new global initiative is taking aim at a longstanding problem in ALS research: the models used to study the disease often fail to reflect the patients researchers are trying to help. PRISM ALS, launched this week across Boston, London and Cambridge, brings together ALS Therapy Development Institute, LifeArc and Axol Bioscience. The goal is straightforward, but ambitious - to expand access to patient-derived stem cell models that better capture the biological complexity of amyotrophic lateral sclerosis (ALS), or motor neurone disease (MND). The initiative, Patient induced pluripotent stem cell (iPSC)-based Research to Improve Sporadic ALS Modelling (PRISM) , will focus on generating well-characterised iPSC-derived motor neuron models. Crucially, these are intended to represent not just rare genetic forms of ALS, but also the far more common sporadic cases. The challenge in ALS drug discovery: models that don’t reflect sporadic disease ALS has always been a difficult disease to study. Around 10–15% of cases are linked to inherited mutations, while roughly 85% are sporadic. Yet many of the models used in drug discovery are based on those rarer genetic subtypes. That disconnect has had knock-on effects, limiting how well targets are validated, narrowing the scope of therapeutic testing, and, ultimately, contributing to the high attrition rate in clinical trials. PRISM ALS is designed to address that gap by building a broader panel of models that better reflect real-world patient biology. For researchers, that should mean more relevant systems for studying disease mechanisms and testing therapies. For drug developers, it offers the possibility of identifying which approaches might work for which patient groups earlier in the pipeline. Patient-derived iPSC models built on longitudinal ALS clinical data The programme draws heavily on ALS TDI’s ALS Research Collaborative (ARC) Study, a longitudinal effort that has been running for over a decade. More than 1,800 people living with ALS have contributed samples and clinical data, creating a resource that links patient biology with disease progression. That depth of data underpins what PRISM ALS is trying to achieve, which are models that are not only biologically, but also clinically, relevant. “We know that ending ALS will require delivering the right treatments to the right individuals,” Dr. Fernando Vieira, CEO and Chief Scientific Officer at ALS TDI. “By characterizing iPSC-derived motor neurons from sporadic ALS and making these cells broadly accessible, PRISM ALS will facilitate global drug discovery. This program is only possible thanks to the people living with ALS who contributed samples and data through the ARC Study.” Scaling standardised iPSC stem cell models for ALS research and drug development A key part of the collaboration is ensuring these models are not just developed, but actually usable at scale. Standardisation and reproducibility remain ongoing challenges in the field, particularly when working with complex human cell systems. Axol Bioscience will play a central role here, providing the infrastructure to manufacture iPSC-derived cells in a consistent and scalable way. Sapna Vyas, Head of Scientific Programs at Axol Bioscience, said: “We’re delighted to participate in this consortium to develop multiple iPSC-derived end point cell types from sporadic ALS iPSC lines that reflect for the first time, real-world variability across age, sex, and genotype. By leveraging Axol’s scalable manufacturing infrastructure, we will facilitate access to standardized iPSC-derived cells that empower researchers to stratify patients, assess subgroup responses to therapies, and reduce late-stage clinical trial failures.” Improving ALS clinical trial success through more predictive disease models Ultimately, the success of PRISM ALS will be measured by whether it improves translation, something the ALS field has struggled with for decades. More representative models won’t solve every challenge, but they could make a meaningful difference. If therapies are tested in systems that better reflect patient diversity from the outset, there is at least a stronger chance that promising results will carry through into the clinic. Paul Wright, Head of MND at LifeArc, added, “Our hope is that the stem cell models we produce can unleash a new generation of treatments that could be effective against this disease by slowing its progression and, ultimately, curing it. We need to do more for people living with MND/ALS, and PRISM ALS brings together leading organizations to help make that happen.” For now, PRISM ALS represents a coordinated attempt to fix a foundational issue in ALS research. If it delivers on that promise, it could quietly, but significantly, shift how the field approaches drug discovery. Author BioFocus Newsroom Previous Next

Antibodies.com has moved to a new, five-times-larger headquarters at Cambridge Technopark to support rapid growth and better serve life science researchers worldwide. < Back Antibodies.com Supercharges UK Operations with Move to Larger Cambridge HQ Antibodies.com has moved to a new, five-times-larger headquarters at Cambridge Technopark to support rapid growth and better serve life science researchers worldwide. Antibodies.com , a leading provider of high-quality reagents for life science research, has today announced the opening of its new UK headquarters at Cambridge Technopark, a significant expansion that marks a new chapter in the company’s rapid global growth. The new 5,000 sq. ft facility, five times larger than its previous site, is designed to boost the company’s logistics, research and development (R&D), and operational capabilities, as it continues to scale with rising international demand. The move reinforces Antibodies.com ’s position within the UK’s thriving biotech cluster and enhances its ability to deliver faster, more customizable solutions to scientists worldwide. “This relocation isn’t just about more space, it’s about unlocking greater potential for innovation and service,” said Dr Stewart Newlove, Chief Technology Officer and Co-Founder of Antibodies.com . “Our new headquarters in the heart of Cambridge’s life sciences community allows us to scale more effectively, improve turnaround times, and continue supporting researchers at the forefront of antibody therapeutics.” Founded to meet the growing demand for affordable, high-performance biological reagents, Antibodies.com has tripled its global customer base in the last five years and now supports over 5,000 research institutions in more than 100 countries. Its extensive product catalogue, featuring over 100,000 items including antibodies, proteins, and ELISA kits, has become a go-to resource for scientists conducting cutting-edge biomedical research. The newly designed headquarters features expanded laboratory and logistics spaces, upgraded infrastructure to improve inventory and fulfilment systems, and state-of-the-art R&D facilities. Designed with sustainability and collaboration in mind, the space also includes shared meeting areas, breakout zones, and secure cycle storage, all aimed at fostering a dynamic and environmentally conscious workplace. With additional offices in Stockholm, Sweden, and St. Louis, USA, this expansion solidifies Antibodies.com ’s international footprint while reaffirming its commitment to customer-centric innovation and operational excellence. Author BioFocus Newsroom Previous Next

Can CagriSema increase the efficacy of obesity treatment and preserve Novo Nordisk's leading position in the market? < Back Novo Nordisk’s CagriSema and the Competitive Dynamics in the Obesity Drug Market Can CagriSema increase the efficacy of obesity treatment and preserve Novo Nordisk's leading position in the market? [Nov 9th, 2024] - Obesity Week 2024 took place last week in San Antonio and, perhaps not unsurprisingly, one of the main topics of discussion was semaglutide, the active ingredient in Wegovy, Novo Nordisk’s flagship obesity drug. Of particular interest was the SELECT study, a randomized, controlled trial which assessed cardiovascular outcomes in patients taking semaglutide vs placebo. For Novo (and of course for obesity patients), new indications for Wegovy that highlight semaglutide’s broader health benefits are great news, but, for the Danish pharmaceutical giant, is this enough amidst an increasingly competitive landscape where rivals such as Eli Lilly are threatening to outperform Wegovy’s weight loss capability? Novo Nordisk’s semaglutide-based drugs, marketed under the brand names Ozempic and Wegovy, have fundamentally transformed the landscape for obesity and diabetes treatment, bringing weight loss capabilities that rival surgical interventions to patients within a simple self-administered dosing pen. Semaglutide, a GLP-1 agonist, has gained substantial market traction and is poised to become the top-selling pharmaceutical product globally in 2024, in the process making Novo Nordisk Europe’s biggest company by market cap. But the competitive environment in the obesity therapeutics market is intensifying rapidly. Novo faces increasing challenges from Eli Lilly’s GLP-1/GIP dual agonist, Zepbound (Mounjaro), and emerging generics as patents near expiration in major markets like the U.S., Europe, and China. In response, Novo is leveraging a new combination therapy, CagriSema, which integrates semaglutide with an amylin analog, cagrilintide. CagriSema could represent the next frontier in multi-receptor obesity treatment, potentially providing superior weight-loss outcomes while maintaining manageable side effects. Here we explore the competitive landscape, the scientific rationale behind CagriSema, its market potential, and the substantial challenges that lie ahead for Novo in the obesity therapeutics space. Competitive Landscape: The GLP-1 Agonist Market and New Entrants The global obesity market is projected to reach $130 billion by 2030, driven by the success of GLP-1 agonists such as Wegovy and the increasing prevalence of obesity and related metabolic diseases. Despite Wegovy’s significant impact, Eli Lilly’s Zepbound has entered the market with compelling efficacy data , showing up to 21% weight reduction in clinical trials compared to Wegovy’s 15% weight reduction. Eli Lilly’s head-to-head trial between Zepbound and Wegovy, expected by year-end, may further highlight the advantages of its dual-action mechanism, positioning it as a formidable competitor. Additionally, Eli Lilly’s triple-agonist compound, retatrutide, targets GLP-1, GIP, and glucagon receptors and has demonstrated up to 24% weight loss in clinical trials, setting a new benchmark in obesity therapy. In this context, Novo’s success with CagriSema hinges on its ability to deliver superior or at least comparable outcomes. CagriSema’s 25% weight-loss target would position it competitively above existing treatments and could help Novo retain market leadership. However, should CagriSema fall short or produce substantial side effects, Novo risks losing its competitive edge to Zepbound and potentially other emerging options, including oral therapies from both Novo and Eli Lilly. The Scientific Foundation of CagriSema: Combining GLP-1 and Amylin CagriSema combines GLP-1 and amylin agonists to harness the complementary mechanisms of these hormones in promoting satiety and weight loss. GLP-1 agonists work by slowing gastric emptying and enhancing insulin secretion, thereby reducing food intake and aiding glycemic control. Amylin, on the other hand, modulates satiety through a distinct neural pathway. The rationale is that amylin’s unique mechanism may reduce the “yo-yo” weight-regain effect commonly seen with obesity drugs, potentially resulting in more sustained weight loss. The inclusion of cagrilintide, an amylin analog, is a strategic decision that could address some limitations of GLP-1 monotherapy. Amylin has shown the potential to extend satiety effects without the gastrointestinal side effects typically associated with GLP-1 therapies, such as nausea and vomiting. The dual action of GLP-1 and amylin in CagriSema could thus offer enhanced weight loss with a more tolerable side-effect profile. This novel approach has attracted considerable interest from competitors, with companies like Zealand Pharma and Eli Lilly developing their own amylin-based candidates. The question that remains, however, is whether CagriSema can deliver on its promise. While preclinical and initial clinical data appear promising, the December readout from CagriSema’s large-scale clinical trial will be crucial. Positive results could solidify amylin’s role as a target in anti-obesity pharmacotherapy and position CagriSema as a leading therapy in the space. However, any failure to meet its weight-loss targets or adverse side-effect revelations could significantly impact Novo’s market position. Addressing the Manufacturing Complexity and Supply Constraints Novo Nordisk has struggled to keep up with global demand for Wegovy and Ozempic, largely due to the supply challenges inherent in biologic production. For CagriSema, the manufacturing demands will be even greater. Unlike single-agent therapies, CagriSema’s formulation requires a dual-chamber syringe to keep the GLP-1 and amylin analogs separate until the point of administration. This dual-chamber technology is complex and has not been commercialized at scale, which may limit Novo’s ability to rapidly meet potential demand. While Novo has invested in expanding its manufacturing facilities to address these issues, the complexity of CagriSema production may slow its rollout and leave Novo vulnerable to supply disruptions, especially as rivals with simpler formulations enter the market. The potential future development of an integrated single-syringe version of CagriSema could alleviate some of these production hurdles. However, this pathway presents additional technical and regulatory challenges and may not be viable in the near term. Shifting Market Dynamics and Emerging Oral Therapeutics While the current market is dominated by injectable biologics, the future of obesity treatment could shift toward oral therapies. Oral delivery options could improve patient adherence and accessibility, particularly for individuals who may be averse to injections. Novo Nordisk and Eli Lilly have both explored oral formulations of GLP-1 and other analogs. However, Novo faces setbacks in this area, as one of its early-stage oral candidates did not meet analysts’ expectations. Eli Lilly’s oral compounds, on the other hand, are showing promise and could soon become a competitive threat. If CagriSema proves successful, Novo could have a temporary advantage, but the long-term market focus may shift toward more convenient oral formulations. For Novo to maintain its market position, it must ensure that its research pipeline includes viable oral candidates and that it can navigate the challenges of manufacturing potent, stable oral biologics—a challenging feat but one that could ultimately secure Novo’s market presence against injectable and generic competitors alike. Strategic Imperatives for Novo Nordisk Novo Nordisk’s journey from a GLP-1 pioneer to a potential leader in multi-receptor obesity therapeutics reflects the company’s innovative and adaptable approach. CagriSema embodies Novo’s next step in advancing obesity pharmacotherapy, combining GLP-1 and amylin’s synergistic effects to potentially deliver superior weight loss outcomes with fewer side effects. Nevertheless, this ambitious project faces formidable challenges, from clinical validation and patent protection to complex manufacturing and competitive pressures. The global obesity drug market is intensifying, with competitors like Eli Lilly pushing the boundaries of multi-receptor agonist therapy, both in injectables and oral formulations. In this high-stakes environment, Novo must execute a twofold strategy: first, deliver CagriSema successfully to market while maintaining its efficacy and safety profile; second, continue to invest in next-generation therapies, particularly in oral formulations, to capture evolving patient preferences. Ultimately, Novo’s future in the obesity market depends on its ability to overcome the immediate challenges and prepare for the shifting competitive dynamics ahead. If Novo succeeds in its ambitious goals for CagriSema and capitalizes on its R&D investments in emerging therapies, it stands a strong chance of preserving its leadership in the multi-billion-dollar obesity drug market. Author BioFocus Newsroom Previous Next

< Back 23rd – 26th June, 2024 Edinburgh, Scotland ESACT 2024 The 28th edition of the annual European Society for Animal Cell Technology Meeting takes place in Edinburgh this year. Previous Register now Next